| Today’s Big NewsFeb 29, 2024 |
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. |
|
| By Max Bayer Novo Nordisk executives unveiled the company's U.S. R&D hub on Wednesday, repurposing Dicerna's old headquarters as the new regional outpost. The event comes as Novo's R&D investments are skyrocketing, thanks to the revenue flooding in from the metabolic franchise. |
|
|
|
By Eric Sagonowsky As it looks to emerge from bankruptcy, Endo agreed to fork over up to $464.9 million to the federal government, which had been investigating the marketing of opioid Opana ER. |
By Andrea Park Shortly after signing off on the first human trial of Neuralink’s brain-computer interface system last year, the FDA reportedly discovered a handful of quality control issues related to the Elon Musk-founded company’s animal experiments of the technology, according to Reuters. |
By Kevin Dunleavy Pfizer’s respiratory syncytial virus vaccine Abrysvo has shown its staying power in a trial of patients who received a single dose before the previous virus season. In season two, Abrysvo provided efficacy of 78% against lower respiratory tract disease in adults 60 and older, according to trial results released Thursday. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Annalee Armstrong In 2022, Kineta swooped in to rescue Yumanity’s immunotherapy from the scrapheap. Now, Kineta needs some rescuing itself. After a strategic review, the small oncology biotech is conducting a corporate restructuring and reducing its workforce by 64%. |
By Eric Sagonowsky As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for a piece of the blockbuster's sales pie. |
By Annalee Armstrong After two years, CytoDyn’s HIV program is finally free of the FDA clinical hold. In a short update Thursday, CEO Jacob Lalezari, M.D., heralded the lifting of the hold as a “new chapter” for lead asset leronlimab. |
By Conor Hale Johnson & Johnson MedTech’s Biosense Webster division has tallied up another regulatory clearance for its pulsed field ablation system, with a CE mark opening up access to Europe. |
By Angus Liu Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional. |
By Andrea Park As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. |
By Nick Paul Taylor Ironwood Pharmaceuticals’ $1 billion short bowel syndrome bet has delivered a phase 3 win—and wiped 30% off the company’s share price. While the study met its primary endpoint, the results failed to convince investors it can win out over Takeda’s Gattex, its potential generic copies and Zealand Pharma’s glepaglutide. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
